Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
Updates in geriatric medical oncology from SIOG meeting ( Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico )
28 Oct 2020
Management of infection risk to myeloma patients during the COVID pandemic
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienn...
Management of infection risk to myeloma patients during the COVID pandemic ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )
1 Oct 2020
Lenalidomide combination for multiple myeloma
Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France
Lenalidomide combination for multiple myeloma ( Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France )
1 Oct 2020
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )
25 Sep 2020
Latest updates to the ESMO bone health guidelines
Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort
Professor Jean-Yves Blay and Professor Florence Duffaud
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk ...
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOda...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Comparative effectiveness of lenalidomide, bortezomib, and their combinations fo...
Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019